OSE IMMUNO : Article Forbes

TibTib912

03 février 2025 •08:39

https://www.forbes.com/sites/lawrencelight/2025/02/02/want-to-make-money-in-biot ech-stocks-check-out-ose-immunotherapeutics/

TibTib912

03 février 2025 •08:40

Posté sur X

TibTib912

03 février 2025 •08:40

Suite post LinkedIn de Nicolas Poirier

TibTib912

03 février 2025 •08:43

Vous voulez faire de l'argent avec les biotechs ? Regardez Ose Immuno

C'est pas moi qui le dit mais Forbes

Raids

03 février 2025 •09:06

le lien ne fonctionne pas !

TibTib912

03 février 2025 •11:21

C'est pas rien un article dans Forbes

On n'est plus dans le rationnel ici

Griskov

03 février 2025 •11:23

TibTib912

03 février 2025 •08:43

Vous voulez faire de l'argent avec les biotechs ? Regardez Ose Immuno

C'est pas moi qui le dit mais Forbes

Ils parlent sûrement de la vade.

M6966522

03 février 2025 •12:10

Want To Make Money In Biotech Stocks? Check Out OSE Immunotherapeutics
Larry Light
Senior Contributor
I write about incisive investing advice.

Feb 2, 2025,09:00am EST Vaccine for cancer as oncology treatment.
Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take a drubbing. But at OSE Immunotherapeutics, which aims to prevent cancers via vaccines, the news is encouraging.
The French company recently announced that it has launched a global Phase 3 trial for its cancer vaccine, Tedopi, which is taking place in the U.S., United Kingdom, Canada and Europe. The trial brings OSE a step closer to regulatory approval for cancer immunization treatment. (There are four phases in the approval process.) OSE in April secured a $9.3 public funding for Tedopi.
Meanwhile, the firm has forged a partnership with pharma giant AbbVie to develop a treatment for chronic inflammation, which came with a $48 million investment from the major drug outfit, a sum that could expand to as much as $665 million if the project meets certain progress milestones. Plus, OSE has expanded its partnership with another big pharma player, Boehringer Ingelheim, centered on therapies for cancer and cardio renal metabolic diseases.
Over the past 12 months, Paris-traded OSE stock has increased 66%. That’s almost triple what the S&P 500 gained. The gamble for investors is whether it will continue to rise. Odds are OSE will, as its product is vitally needed and stands to be in the vanguard of cancer treatments.
“Every day, the immune system is fighting and eliminating cancer cells,” said Nicolas Poirier, OSE’s CEO, in an interview. “Immunotherapies have revolutionized cancer treatment, offering cures for some, but not all types of cancer. We must continue to push on the gas pedal.”

M6966522

03 février 2025 •12:12

Rien à voie avec de la VADE. Article très positif ..

Pyla07

03 février 2025 •12:34

Ose est devenue ma plus grosse ligne depuis ce matin...

Good_feeling

03 février 2025 •12:56

j'en ai repris aussi un peu sur le tard malheureusement.